Investors

Edesa Biotech – Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. We have multiple late-stage product candidates in our development pipeline in the fields of  medical dermatology and respiratory diseases.

In dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody, as therapy for vitiligo,  a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play both a key role in the disease and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. We have received regulatory approval from Health Canada to conduct a Phase 2 study of EB06 in patients with moderate-to-severe non-segmental vitiligo and we are in discussions with the FDA for the same study. Our derm program also includes EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for Allergic Contact Dermatitis, a common occupational skin condition.

Our most advanced respiratory drug candidate is EB05 (paridiprubart). EB05 represents a new class of therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body’s own immune response when confronted with infectious diseases or even chemical agents. EB05 is being evaluated in a U.S. government-funded Phase 2 platform study of HDTs. We have also been awarded Canadian government funding to support this development program. In addition, we are preparing an IND for a future Phase 2 study of paridiprubart in patients with pulmonary fibrosis.